- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04404569
Continued Treatment for Participants Enrolled in Studies of BXQ-350 (ETERNITI)
An Open-Label, Multi-Center, Rollover Study to Provide Continued Treatment Access for Participants Enrolled in Studies of BXQ-350
Study Overview
Detailed Description
This is an open-label, multi-center, rollover study to allow continued treatment access for participants enrolled in studies of BXQ-350. This study is intended for subjects who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study, and who are judged by the Investigator to benefit from continued treatment with BXQ-350. The additional treatment is optional and voluntary.
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky Markey Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati Barrett Center
-
Columbus, Ohio, United States, 43210
- The Ohio State University Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Each subject must meet the following criteria:
- Has participated in and completed all protocol-specified treatments through the required study observation period or time of closure for a prior Bexion-sponsored BXQ-350 clinical study
- Has completed the End of Study visit of the prior Bexion-sponsored BXQ-350 clinical study
- Did not meet any treatment discontinuation criteria of the original prior Bexion- sponsored BXQ-350 clinical study
- Investigator opinion indicates that continued treatment with BXQ-350 is clinically appropriate for the subject
- Provide signed, written informed consent prior to the initiation of any study-specific procedures (Consent from Guardians for minor children and patient assent according to Institution and Institutional Review Board (IRB) standards)
- Have a negative serum pregnancy test result within 28 days prior to the first continuing treatment assessment for females of child bearing potential (FCBP); not applicable to subjects who are unable to become pregnant, including those with tubal ligation, bilateral oophorectomy and/or hysterectomy)
FCBP and male subjects whose sexual partner(s) are FCBP must agree to abstain from heterosexual activity or use a double barrier method of contraception (e.g., condom and occlusive cap with spermicide) or highly effective contraception (intrauterine device or system, established hormonal contraceptive methods on a stable dose from the time of the last menstrual cycle, or vasectomized partner with confirmed azoospermia) from the time of study entry to 1 month after the last day of treatment
Exclusion Criteria:
Subjects must not meet any of the following criteria:
- Has any ongoing adverse event that could impact tolerability to BXQ-350
- Receiving any other non-BXQ-350 study treatment modalities with curative intent, including investigational products other than BXQ-350
- Are pregnant or nursing (lactating), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum human chorionic gonadotropin (hCG) laboratory test
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Continued Treatment
Subjects who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study, and who are judged by the Investigator to benefit from continued treatment with BXQ-350. Treatment will begin after completion of the End of Study visit of the prior BXQ-350 clinical study. The established safe dose of BXQ-350 from previous adult and pediatric phase 1 studies is 2.4 mg/kg and 3.2 mg/kg respectively once every 28 days (± 3 days). BXQ-350 will be administered intravenously at the same dose level and frequency the subject was receiving at the end of the prior BXQ-350 clinical study. Subjects receiving a reduced dose at the end of the prior BXQ-350 clinical study due to toxicity may continue to receive a reduced dose. |
BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350).
BXQ-350 is administered by intravenous (IV) infusion in 28-day cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of subjects with clinical benefit
Time Frame: Day 1 up to approximately 5 years
|
Subjects will be assessed at every visit for continued clinical benefit as per Investigator's assessment.
|
Day 1 up to approximately 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0
Time Frame: Day 1 up to approximately 5 years
|
Subjects will be assessed at every visit for adverse events
|
Day 1 up to approximately 5 years
|
Time to Disease Progression
Time Frame: From Day 1 until the date of first documented disease progression or date of death from any cause, whichever occurs first; up to approximately 5 years
|
Subjects will be assessed for disease progression throughout the study per institutional standard of care.
|
From Day 1 until the date of first documented disease progression or date of death from any cause, whichever occurs first; up to approximately 5 years
|
Overall Survival
Time Frame: From date of BXQ-350 treatment completion until time of death from any cause; up to approximately 5 years
|
Subjects will be followed monthly for survival upon completion of BXQ-350 treatment.
|
From date of BXQ-350 treatment completion until time of death from any cause; up to approximately 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- BXQ-350.AE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI); Department of Health and Human Services; Early... and other collaboratorsRecruitingColonic NeoplasmsUnited States, Canada, Australia
Clinical Trials on BXQ-350
-
Bexion Pharmaceuticals, Inc.CTI Clinical Trial and Consulting ServicesRecruitingDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-MutantUnited States
-
Bexion Pharmaceuticals, Inc.CTI Clinical Trial and Consulting ServicesTerminatedNeoplasmsUnited States
-
Bexion Pharmaceuticals, Inc.CTI Clinical Trial and Consulting ServicesCompleted
-
Bexion Pharmaceuticals, Inc.CTI Clinical Trial and Consulting ServicesRecruitingChemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Bexion Pharmaceuticals, Inc.ICON plc; CTI Clinical Trial and Consulting ServicesRecruitingNeuropathy | Metastatic Colorectal CarcinomaUnited States
-
Cerevel Therapeutics, LLCRecruiting
-
The Baruch Padeh Medical Center, PoriyaUnknownOsteoarthritis of Acromioclavicular Joint
-
Credit Valley EyeCareGlaucoma Research Society of CanadaCompletedGlaucomaUnited States, Canada, Chile